Zentalis Pharma Posts Initial Clinical Data On Its Wee1 Inhibitor In Ovarian Cancer

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) announced initial efficacy and safety data from the ongoing Phase 1b trial of ZN-c3 combined with chemotherapy in patients with platinum-resistant or -refractory ovarian cancer. 

• Data were reviewed at the American Association of Cancer Research (AACR) Annual Meeting.
• The study consists of four cohorts: ZN-c3 + PLD, ZN-c3 + carboplatin, ZN-c3 + paclitaxel, and ZN-c3 + gemcitabine.
• ZN-c3, in combination with chemotherapy, demonstrated anti-tumor activity in a heavily pretreated population, with an objective response rate (ORR) of 30.2% across all evaluable chemotherapy cohorts.
• ZN-c3 + paclitaxel cohort achieved an ORR of 62.5%.
• ZN-c3 was generally well-tolerated in combination with chemotherapy and exhibited lower hematologic toxicity and a better gastrointestinal tolerability profile than the Wee1 inhibitor class.
• The most common treatment-related adverse events at all grades included nausea (48.2%), neutropenia (41.1%), thrombocytopenia (37.5%), vomiting (30.4%), and anemia (26.8%).
• Price Action: On Friday, ZNTL shares gained 4.95% to $35.65 in after-hours trading.